Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection
Status:
Withdrawn
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The scientific community is in search for novel therapies that can help to face the ongoing
epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present,
there are no proven interventions to prevent progression of the disease. Some preliminary
data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects
on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we
will test whether inhaled NO therapy prevents progression in patients with mild to moderate
COVID-19 disease.
Phase:
Phase 2
Details
Lead Sponsor:
Xijing Hospital
Collaborators:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Massachusetts General Hospital